# Mannkind Corp: financial statements, quarterly

MNKD · Nasdaq · CIK 899460 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mnkd.md) · [Financials](/companies/mnkd/financials.md) · [Filings](/companies/mnkd/filings.md) · [Insiders](/companies/mnkd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mnkd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [51.3](/filings/0000950170-24-123296.md) | [58.5 d](/filings/0001193125-26-073516.md) | [66.3](/filings/0000950170-25-066429.md) | [72.4](/filings/0000950170-25-103535.md) | [70.1](/filings/0001193125-25-265813.md) | [76.8 d](/filings/0001193125-26-073516.md) | [78.4](/filings/0001193125-26-208916.md) | [76.5](/filings/0001193125-26-335054.md) | [82.1](/filings/0001193125-25-265813.md) | [112 d](/filings/0001193125-26-073516.md) | [90.2](/filings/0001193125-26-208916.md) | [109](/filings/0001193125-26-335054.md) |
| Cost of revenue | $m | [4.0](/filings/0000950170-24-123296.md) | [6.1 d](/filings/0001193125-26-073516.md) | [3.8](/filings/0000950170-25-066429.md) | [5.6](/filings/0000950170-25-103535.md) | [3.2](/filings/0001193125-25-265813.md) | [4.8 d](/filings/0001193125-26-073516.md) | [3.8](/filings/0001193125-26-208916.md) | [4.6](/filings/0001193125-26-335054.md) | [4.5](/filings/0001193125-25-265813.md) | [13.9 d](/filings/0001193125-26-073516.md) | [7.5](/filings/0001193125-26-208916.md) | [14.4](/filings/0001193125-26-335054.md) |
| Selling, general and administrative | $m | not reported | not reported | [22.3](/filings/0000950170-25-066429.md) | [24.1](/filings/0000950170-25-103535.md) | [23.9](/filings/0001193125-25-265813.md) | [24.0 d](/filings/0001193125-26-073516.md) | [25.0](/filings/0001193125-26-208916.md) | [31.6](/filings/0001193125-26-335054.md) | [29.1](/filings/0001193125-25-265813.md) | [58.4 d](/filings/0001193125-26-073516.md) | [54.1](/filings/0001193125-26-208916.md) | [58.3](/filings/0001193125-26-335054.md) |
| Operating income | $m | [5.1](/filings/0000950170-24-123296.md) | [7.9 d](/filings/0001193125-26-073516.md) | [16.7](/filings/0000950170-25-066429.md) | [16.6](/filings/0000950170-25-103535.md) | [12.8](/filings/0001193125-25-265813.md) | [26.5 d](/filings/0001193125-26-073516.md) | [22.3](/filings/0001193125-26-208916.md) | [5.3](/filings/0001193125-26-335054.md) | [18.9](/filings/0001193125-25-265813.md) | [(7.7) d](/filings/0001193125-26-073516.md) | [(1.7)](/filings/0001193125-26-208916.md) | [(0.4)](/filings/0001193125-26-335054.md) |
| Interest expense | $m | [2.8](/filings/0000950170-23-060253.md) | [2.7 d](/filings/0000950170-24-021423.md) | [2.6](/filings/0000950170-24-055661.md) | [6.1](/filings/0000950170-24-092288.md) | [1.8](/filings/0001193125-25-265813.md) | [1.6 d](/filings/0001193125-26-073516.md) | [4.6](/filings/0001193125-26-208916.md) | [0.3](/filings/0001193125-26-335054.md) | [1.4](/filings/0001193125-25-265813.md) | [7.5 d](/filings/0001193125-26-073516.md) | [7.5](/filings/0001193125-26-208916.md) | [11.9](/filings/0001193125-26-335054.md) |
| Income tax | $m | [0.0](/filings/0000950170-23-060253.md) | [1.6 d](/filings/0001193125-26-073516.md) | [0.3](/filings/0000950170-25-066429.md) | [0.3](/filings/0000950170-25-103535.md) | [1.3](/filings/0001193125-25-265813.md) | [1.0 d](/filings/0001193125-26-073516.md) | [0.5](/filings/0001193125-26-208916.md) | [0.3](/filings/0001193125-26-335054.md) | [(0.2)](/filings/0001193125-25-265813.md) | [(5.0) d](/filings/0001193125-26-073516.md) | [0.3](/filings/0001193125-26-208916.md) | [(0.1)](/filings/0001193125-26-335054.md) |
| Net income | $m | [1.7](/filings/0000950170-24-123296.md) | [1.4 d](/filings/0001193125-26-073516.md) | [10.6](/filings/0001193125-25-265813.md) | [(2.0)](/filings/0001193125-25-265813.md) | [11.6](/filings/0001193125-25-265813.md) | [7.4 d](/filings/0001193125-26-073516.md) | [13.2](/filings/0001193125-26-335054.md) | [0.7](/filings/0001193125-26-335054.md) | [8.0](/filings/0001193125-25-265813.md) | [(15.9) d](/filings/0001193125-26-073516.md) | [(16.6)](/filings/0001193125-26-335054.md) | [(19.0)](/filings/0001193125-26-335054.md) |
| Diluted EPS | $ per share | [0.01](/filings/0000950170-24-123296.md) | not reported | [0.04](/filings/0000950170-25-066429.md) | [(0.01)](/filings/0000950170-25-103535.md) | [0.04](/filings/0001193125-25-265813.md) | not reported | [0.04](/filings/0001193125-26-208916.md) | [0.00](/filings/0001193125-26-335054.md) | [0.03](/filings/0001193125-25-265813.md) | not reported | [(0.05)](/filings/0001193125-26-208916.md) | [(0.06)](/filings/0001193125-26-335054.md) |
| Basic EPS | $ per share | [0.01](/filings/0000950170-24-123296.md) | not reported | [0.04](/filings/0000950170-25-066429.md) | [(0.01)](/filings/0000950170-25-103535.md) | [0.04](/filings/0001193125-25-265813.md) | not reported | [0.04](/filings/0001193125-26-208916.md) | [0.00](/filings/0001193125-26-335054.md) | [0.03](/filings/0001193125-25-265813.md) | not reported | [(0.05)](/filings/0001193125-26-208916.md) | [(0.06)](/filings/0001193125-26-335054.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [83.0](/filings/0000950170-23-060253.md) | [238](/filings/0000950170-25-027735.md) | [193](/filings/0000950170-24-055661.md) | [96.6](/filings/0000950170-24-092288.md) | [62.4](/filings/0000950170-24-123296.md) | [46.3](/filings/0001193125-26-073516.md) | [47.3](/filings/0000950170-25-066429.md) | [57.0](/filings/0000950170-25-103535.md) | [127](/filings/0001193125-25-265813.md) | [74.9](/filings/0001193125-26-335054.md) | [52.8](/filings/0001193125-26-208916.md) | [52.9](/filings/0001193125-26-335054.md) |
| Current assets | $m | [226](/filings/0000950170-23-060253.md) | [373](/filings/0000950170-25-027735.md) | [383](/filings/0000950170-24-055661.md) | [326](/filings/0000950170-24-092288.md) | [328](/filings/0000950170-24-123296.md) | [268](/filings/0001193125-26-073516.md) | [274](/filings/0000950170-25-066429.md) | [279](/filings/0000950170-25-103535.md) | [359](/filings/0001193125-25-265813.md) | [292](/filings/0001193125-26-335054.md) | [251](/filings/0001193125-26-208916.md) | [246](/filings/0001193125-26-335054.md) |
| Total assets | $m | [320](/filings/0000950170-23-060253.md) | [475](/filings/0000950170-25-027735.md) | [481](/filings/0000950170-24-055661.md) | [444](/filings/0000950170-24-092288.md) | [464](/filings/0000950170-24-123296.md) | [394](/filings/0001193125-26-073516.md) | [410](/filings/0000950170-25-066429.md) | [412](/filings/0000950170-25-103535.md) | [495](/filings/0001193125-25-265813.md) | [792](/filings/0001193125-26-335054.md) | [744](/filings/0001193125-26-208916.md) | [732](/filings/0001193125-26-335054.md) |
| Current liabilities | $m | [96.4](/filings/0000950170-23-060253.md) | [104](/filings/0000950170-25-027735.md) | [99.9](/filings/0000950170-24-055661.md) | [80.0](/filings/0000950170-24-092288.md) | [72.1](/filings/0000950170-24-123296.md) | [81.8](/filings/0001193125-26-073516.md) | [116](/filings/0000950170-25-066429.md) | [112](/filings/0000950170-25-103535.md) | [109](/filings/0001193125-25-265813.md) | [171](/filings/0001193125-26-335054.md) | [135](/filings/0001193125-26-208916.md) | [143](/filings/0001193125-26-335054.md) |
| Total liabilities | $m | [572](/filings/0000950170-23-060253.md) | [721](/filings/0000950170-25-027735.md) | [711](/filings/0000950170-24-055661.md) | [670](/filings/0000950170-24-092288.md) | [674](/filings/0000950170-24-123296.md) | [473](/filings/0001193125-26-073516.md) | [469](/filings/0000950170-25-066429.md) | [467](/filings/0000950170-25-103535.md) | [539](/filings/0001193125-25-265813.md) | [843](/filings/0001193125-26-335054.md) | [804](/filings/0001193125-26-208916.md) | [800](/filings/0001193125-26-335054.md) |
| Long-term debt | $m | [273](/filings/0000950170-23-060253.md) | [269](/filings/0000950170-25-027735.md) | [264](/filings/0000950170-24-055661.md) | [228](/filings/0000950170-24-092288.md) | [228](/filings/0000950170-24-123296.md) | [36.1](/filings/0001193125-26-073516.md) | [36.1](/filings/0000950170-25-066429.md) | [36.2](/filings/0000950170-25-103535.md) | [110](/filings/0001193125-25-265813.md) | [355](/filings/0001193125-26-073516.md) | [319](/filings/0001193125-26-208916.md) | [319](/filings/0001193125-26-335054.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(252)](/filings/0000950170-24-123296.md) | [(246)](/filings/0001193125-26-073516.md) | [(230)](/filings/0001193125-25-265813.md) | [(226)](/filings/0001193125-25-265813.md) | [(210)](/filings/0001193125-25-265813.md) | [(78.8)](/filings/0001193125-26-335054.md) | [(58.6)](/filings/0001193125-26-335054.md) | [(55.0)](/filings/0001193125-26-335054.md) | [(44.6)](/filings/0001193125-25-265813.md) | [(51.0)](/filings/0001193125-26-335054.md) | [(59.2)](/filings/0001193125-26-335054.md) | [(67.2)](/filings/0001193125-26-335054.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [8.7 d](/filings/0000950170-24-123296.md) | [21.7 d](/filings/0001193125-26-073516.md) | [6.7](/filings/0000950170-25-066429.md) | [3.8 d](/filings/0000950170-25-103535.md) | [9.3 d](/filings/0001193125-25-265813.md) | [22.6 d](/filings/0001193125-26-073516.md) | [(6.4)](/filings/0001193125-26-208916.md) | [9.0 d](/filings/0001193125-26-335054.md) | [23.6 d](/filings/0001193125-25-265813.md) | [(8.0) d](/filings/0001193125-26-073516.md) | [(5.4)](/filings/0001193125-26-208916.md) | [(18.4) d](/filings/0001193125-26-335054.md) |
| Capital expenditure | $m | [11.4 d](/filings/0000950170-24-123296.md) | [5.9 d](/filings/0001193125-26-073516.md) | [2.4](/filings/0000950170-25-066429.md) | [3.0 d](/filings/0000950170-25-103535.md) | [1.4 d](/filings/0001193125-25-265813.md) | [2.9 d](/filings/0001193125-26-073516.md) | [0.3](/filings/0001193125-26-208916.md) | [1.1 d](/filings/0001193125-26-335054.md) | [1.1 d](/filings/0001193125-25-265813.md) | [2.0 d](/filings/0001193125-26-073516.md) | [1.9](/filings/0001193125-26-208916.md) | [5.1 d](/filings/0001193125-26-335054.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [259](/filings/0000950170-23-060253.md) | [264](/filings/0000950170-24-055661.md) | [266](/filings/0000950170-24-092288.md) | [324](/filings/0000950170-24-123296.md) | [325](/filings/0000950170-25-066429.md) | [273](/filings/0000950170-25-103535.md) | [285](/filings/0001193125-25-265813.md) | [321](/filings/0001193125-26-208916.md) | [311](/filings/0001193125-26-335054.md) | [312](/filings/0001193125-25-265813.md) | [308](/filings/0001193125-26-208916.md) | [309](/filings/0001193125-26-335054.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 321,540,637 at 2026-07-24, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335054.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.